Mitigate (ATD)

- Finalize development of comprehensive searchable repository for repurposed drug candidates containing supporting data for biothreat pathogen applications. - Advance broad spectrum, repurposed pharmaceutical candidates with biodefense evidence toward later-stage development or clinical practice guideline establishment. - Initiate…

- Execute efficacy testing across diverse pathogens and chemical exposures to address respiratory distress, neurocognitive impairment, and vascular dysfunction. - Perform immune modulation effectiveness studies to reduce symptoms induced by viral pathogens. - Validation of efficacy and safety platforms for human-directed therapies to…

FY2027 planned work - Conduct field demonstrations and transition technologies and methods for chemical and biological tactical and thorough decontamination of aircraft (e.g., helicopter) interiors and exteriors. - Demonstrate and transition portable aqueous hydrogen peroxide generator for on-site production of decontaminant to reduce the burden of sensitive equipment decontamination. - Demonstrate new decontaminants and decontamination processes, including vesicant disclosure to reduce the burden of decontamination and support sensitive equipment return to normal operations. - Demonstrate and transition semi-autonomous vehicle decontamination subsystems and systems to reduce troop labor and risk during…

FY2026 to FY2027 change Increase to support demonstration and user assessments for semi-autonomous vehicle decontamination system.

FY2026 plans — current year - Demonstrate integration of subsystems and modular payloads for autonomous equipment decontamination subsystems to reduce troop-to-task and logistics requirements for operational decontamination. - Conduct technology readiness assessment of technologies and methods for chemical and biological tactical and thorough decontamination of aircraft (e.g., helicopter) interiors and exteriors. - Continue to develop portable aqueous hydrogen peroxide generator for on-site production of decontaminant to reduce the burden of sensitive equipment decontamination.

FY2025 accomplishments - Demonstrate autonomous equipment decontamination subsystems to reduce troop-to-task and logistics requirements for operational decontamination. - Conduct field demonstration of technologies and methods for chemical and biological tactical and thorough decontamination of aircraft (e.g., helicopter) interiors and exteriors.

FY2027 planned work - Complete demonstration of biological disinfection guidelines, procedures, and Concepts of Operations (CONOPs) for DoW facilities and large-platform interiors, including development of directed energy disinfection methods including plasma and ultraviolet germicidal irradiation. - Conduct field demonstration to prove out operational relevancy.

FY2026 to FY2027 change Increase completes critical laboratory validation of biological disinfection guidelines and methods for facility and large-platform interiors in FY 2027 and transitions operationally relevant biological threat surrogate performance data for use in future decontamination technology field demonstrations.

FY2026 plans — current year - Complete laboratory feasibility study for biological agent disclosure spray formulations for sensitive, specific biological contamination mapping on surfaces to guide and reduce logistics of decontamination.

FY2025 accomplishments - Demonstrate biological disinfection guidelines, procedures, and Concepts of Operations (CONOPs) for DoW facilities and large-platform interiors, including development of directed energy disinfection methods including plasma and ultraviolet germicidal irradiation. - Continue to develop biological agent disclosure sprays for sensitive, specific biological contamination mapping on surfaces to guide and reduce logistics of decontamination. - Continue research, development, and demonstration of one or more functional prototype technologies in a phased approach for a biological agent disclosure sprays and down select designs for further development.

FY2027 planned work - Continue preclinical studies for one lead drug candidate to meet FDA approval requirements in preparation for IND submission to the FDA.

FY2026 to FY2027 change Program/project funding transferred to another funding line. Funding transferred to Project PT3/Protect for Nerve Agent Prophylaxis acceleration.

FY2026 plans — current year - Continue to optimize processes and perform preclinical studies for lead drug candidate to meet FDA approval requirements. - Continue development efforts in preparation for IND/phase 1 clinical trials, including current good manufacturing practices (cGMP) manufacturing.

FY2025 accomplishments - Continued to perform preclinical studies for lead drug candidate and optimize processes for meeting the set of quality regulations established by the FDA. - Initiated pre-investigative new drug (pre-IND) package submission for one drug candidate.

FY2027 planned work - Validate AI-based pathogenesis prediction capabilities. - Assess AI target identification and medical countermeasure prediction tools. - Transition forecasting platform for pathogenesis and medical countermeasure analysis to advanced development. - Transition organoid platform for predicting and evaluating antibody off-target binding to advanced development.

FY2026 to FY2027 change FY 2026 to FY 2027 decrease due to divestment in PATMOS organoid program and reduced efforts to complete DOMANE-ENBD activities in FY 2027.

FY2026 plans — current year - Continue development of alternative evaluation platforms to predict and assess MCM safety for Food and Drug Administration (FDA) MCM licensure. - Continue development of alternative evaluation platforms to characterize disease progression to enable identification of biomarkers of disease. - Continue development of alternative evaluation platforms to incorporate immune components for testing of prophylaxis and host-directed therapeutics. - Transition initial Pathogenesis and Toxicity Forecasting Using Multi-Organoid System (PATMOS) prototype to Enabling Biotechnologies. - Continue MCM efficacy testing in alternative evaluation platforms against biological toxins and viral threats.

FY2025 accomplishments - Continued development of organoid platform to predict and assess MCM safety. - Continued to use organoid platform to characterize disease progression. - Continued to identify potential drug candidates utilizing various AI/ML-supported platforms.

FY2027 planned work - Complete development of initial prototype for semi-autonomous robotic platform and spray payload for biological decontamination of mission critical areas. - Conduct test bed demonstration of a prototype autonomous biological critical area decontamination system with decontaminant formulation for effectiveness in biological threat decontamination in operationally relevant field testing.

FY2026 to FY2027 change Increase completes decontaminant formulation optimization and operationally relevant demonstrations to transition autonomous decontamination system prototypes for advanced development.

FY2025 accomplishments - Demonstrate chemical and biological critical area decontamination formulations methods. - Validate processes for using commercially available packaged chemicals and operationally-relevant environments and simulants. - Demonstrate formulation efficacy in operationally relevant field testing.

FY2027 planned work - Transition initial formulation for chemical decontamination of mission-critical areas to enable safe traversal of vehicles, rapid return to mission, and minimize spread of hazard.

FY2026 plans — current year - Complete materials compatibility study for optimized critical area decontamination formulation. - Complete cost analysis for large scale use of commercially available packaged chemicals for decontaminating critical infrastructure. - Demonstrate optimized formulation effectiveness in operationally relevant field testing.

FY2025 accomplishments - Demonstrate chemical and biological critical area decontamination formulations methods. - Validate processes for using commercially available packaged chemicals and operationally relevant environments and simulants. - Demonstrate formulation efficacy in operationally relevant field testing.

FY2027 planned work - Engineer composite materials for proof-of-concept performance and transition to applied research in hazard mitigation thrusts. - Integrate materials into coatings and decontaminants with maximum agent repellency, sorption, and reactivity and investigate scaled production. - Perform iterative decontamination testing on novel reactive materials to determine potential for chemical threat detoxification.

FY2026 to FY2027 change Increase to support development of scaled manufacturing methods for novel materials.

FY2026 plans — current year - Optimize scaled materials manufacturing processes for cost and process efficiency and transition to hazard mitigation thrusts.

FY2025 accomplishments - Optimize scaled materials manufacturing processes for cost and process efficiency and transition to Protective Garments thrust. - Characterize materials using operationally relevant test methods.

FY2026 to FY2027 change Program/project is entering completion and all activities will be closed. In FY 2026, CROWD will close-out to transfer to Nerve Agent Prophylaxis efforts under Project PT3/Protect.

FY2026 plans — current year - Close-out to transfer to Nerve Agent Prophylaxis efforts.

FY2025 accomplishments - Performed preclinical studies to validate safety and efficacy in support of clinical trials and optimize processes for meeting the set of quality regulations established by the FDA.

FY2026 to FY2027 change Program/project funding transferred to another funding line. Funding transferred to Nerve Agent Prophylaxis to accelerate candidates.

FY2026 plans — current year - Continue to find medicine candidates that treat key symptoms regardless of the specific agent that is causing them.

FY2025 accomplishments - Continued to find medicine candidates that treat key symptoms regardless of the specific agent that is causing them. This moves us away from “one risk, one remedy” solutions.

FY2025 accomplishments - Complete test method development for temporary overcoat evaluation to reduce chemical agent repellency and decontamination burden for current military equipment coatings.

FY2026 to FY2027 change Decrease due to project completion.

FY2026 plans — current year - Complete data package to support Food and Drug Administration (FDA) review of a powder/dry decontamination kit that reduces sustainment risk of Reactive Skin Decontamination Lotion (RSDL) cold storage and shelf-life concerns for general purpose warfighter personnel decontamination. - Select modified commercially available personnel decontamination technology as potential alternative to RSDL for unbroken skin. - Complete laboratory effectiveness and safety testing of sorptive and reactive materials and processes for integration into future unbroken skin decontamination products.

FY2025 accomplishments - Continued laboratory evaluation of commercial and developmental systems for Personnel Decontamination that reduces sustainment risk of Reactive Skin Decontamination Lotion (RSDL) cold storage and shelf-life concerns for general purpose warfighter personnel decontamination. - Completed development of improved processes to test removal of chemical contamination from skin surfaces during personnel decontamination